Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status

Taichi MatsubaraDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanCorrespondence[email protected]
View further author information

Takashi SetoDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Shinkichi TakamoriDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Takatoshi FujishitaDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Ryo ToyozawaDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Kensaku ItoDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Masafumi YamaguchiDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Tatsuro OkamotoDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information

Articles from other publishers (10)